Why is Jagsonpal Pharma falling/rising?

As of 09-Jul, Jagsonpal Pharmaceuticals Ltd is experiencing a price increase, currently at 231.15, which reflects a rise of 2.1 or 0.92%. The stock has outperformed its sector today by 0.72%, and it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past year, the stock has generated a remarkable return of 71.22%, significantly outperforming the market benchmark, which only returned 1.43%. However, there has been a notable decline in investor participation, with delivery volume falling by 45.83% against the 5-day average. The company maintains a low debt-to-equity ratio and has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 42.15%. Positive results over the last four consecutive quarters, including a 107.03% growth in PAT and a 39.54% increase in net sales, further support the stock's upward movement.
In the broader market context, the stock's short-term return of +0.74% over the past week is significantly higher than the benchmark Sensex, which only increased by 0.15%. Despite a slight decline of 0.79% over the past month compared to the Sensex's gain of 1.32%, the long-term performance of Jagsonpal Pharmaceuticals remains strong, particularly with a staggering 1192.79% increase over the past five years, compared to the benchmark's 127.39%. This indicates that while there may be some short-term fluctuations, the overall trajectory of the stock is positive, bolstered by strong fundamentals and consistent performance.